Research from the University of Cincinnati reveals how the MYC oncogene alters PRPS enzymes, impacting redox homeostasis and ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

CD70 expression increased cytotoxicity of CD70 CAR NK cells against osteosarcoma; however, upregulation of CD70 had no effect on cytotoxicity.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing ...

Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced melanoma. Read the latest REPL stock analysis here.

The discovery, published in Cancer Immunology Research, could pave the way for new, more powerful immunotherapies for difficult-to-treat cancers. NK cells, or natural killer cells, are white blood ...